Chemoinformaics analysis of 6-diazo-5-oxo-L-norleucine
| Molecular Weight | 171.156 | nRot | 5 |
| Heavy Atom Molecular Weight | 162.084 | nRig | 4 |
| Exact Molecular Weight | 171.064 | nRing | 0 |
| Solubility: LogS | -1.093 | nHRing | 0 |
| Solubility: LogP | -1.265 | No. of Aliphatic Rings | 0 |
| Acid Count | 1 | No. of Aromatic Rings | 0 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 21 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 12 | No. of Aromatic Carbocycles | 0 |
| nHetero | 6 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 9 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 6 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 3 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 0 |
| nHA | 3 | APOL | 21.7271 |
| nHD | 2 | BPOL | 10.7649 |
| QED | 0.347 |
| Synth | 4.776 |
| Natural Product Likeliness | 0.844 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0 |
| Pgp-sub | 0.103 |
| HIA | 0.933 |
| CACO-2 | -6.124 |
| MDCK | 0.00508183 |
| BBB | 0.727 |
| PPB | 0.235657 |
| VDSS | 0.337 |
| FU | 0.797715 |
| CYP1A2-inh | 0.024 |
| CYP1A2-sub | 0.068 |
| CYP2c19-inh | 0.064 |
| CYP2c19-sub | 0.045 |
| CYP2c9-inh | 0.043 |
| CYP2c9-sub | 0.143 |
| CYP2d6-inh | 0.06 |
| CYP2d6-sub | 0.331 |
| CYP3a4-inh | 0.007 |
| CYP3a4-sub | 0.028 |
| CL | 2.089 |
| T12 | 0.897 |
| hERG | 0.022 |
| Ames | 0.993 |
| ROA | 0.023 |
| SkinSen | 0.765 |
| Carcinogencity | 0.928 |
| EI | 0.719 |
| Respiratory | 0.502 |
| NR-Aromatase | 0.004 |
| Antiviral | No |
| Prediction | 0.87482 |